Compound
|
Mechanism
|
Area Under Investigation
|
Date Commenced Phase
|
Estimated Filing
|
|||
US
|
EU
|
Japan
|
China
|
||||
Cardiovascular
|
|||||||
Brilinta/ Brilique EUCLID
|
ADP receptor antagonist
|
outcomes study in patients with PAD
|
4Q 2012
|
2016
|
2016
|
2016
|
2017
|
Brilinta / Brilique PEGASUS-TIMI 54
|
ADP receptor antagonist
|
outcomes study in patients with prior MI
|
4Q 2010
|
2015
|
2015
|
2015
|
2017
|
Brilinta/ Brilique SOCRATES1
|
ADP receptor antagonist
|
outcomes study in patients with stroke or TIA
|
1Q 2014
|
2016
|
2016
|
2016
|
2017
|
Brilinta/ Brilique THEMIS
|
ADP receptor antagonist
|
outcomes study in patients with Type 2 diabetes and CAD but without previous history of MI or stroke
|
2017
|
2017
|
2018
|
2018
|
|
Bydureon Dual Chamber Pen
|
GLP-1 receptor agonist
|
diabetes
|
Filed
|
Filed
|
2Q 2014
|
||
Bydureon EXSCEL
|
GLP-1 receptor agonist
|
outcomes study
|
2Q 2010
|
2018
|
2018
|
2018
|
|
Bydureon weekly suspension
|
GLP-1 receptor agonist
|
diabetes
|
1Q 2013
|
2015
|
2015
|
||
Farxiga/Forxiga2 DECLARE
|
SGLT2 inhibitor
|
outcomes study
|
2Q 2013
|
2020
|
2020
|
||
Kombiglyze XR/ Komboglyze FDC3
|
DPP-4 inhibitor/
metformin FDC
|
diabetes
|
Launched
|
Launched
|
Filed
|
||
Onglyza SAVOR-TIMI 53
|
DPP-4 inhibitor
|
outcomes study
|
2Q 2010
|
1Q 2014
|
1Q 2014
|
2015
|
|
saxagliptin/
dapagliflozin FDC
|
DPP-4 inhibitor/SGLT2 inhibitor FDC
|
diabetes
|
2Q 2012
|
2015
|
2015
|
||
Xigduo
|
SGLT2 inhibitor/
metformin FDC
|
diabetes
|
Filed
|
Approved4
|
Compound
|
Mechanism
|
Area Under Investigation
|
Date Commenced Phase
|
Estimated Filing
|
||||
US
|
EU
|
Japan
|
China
|
|||||
Gastrointestinal
|
||||||||
Entocort
|
glucocorticoid steroid
|
Crohn's disease/ulcerative colitis
|
Launched
|
Launched
|
2015
|
N/A
|
||
Linaclotide#
|
GC-C receptor peptide agonist
|
irritable bowel syndrome with constipation (IBS-C)
|
N/A
|
N/A
|
N/A
|
2015
|
||
Nexium
|
proton pump inhibitor
|
peptic ulcer bleeding
|
Filed5
|
Launched
|
N/A
|
Launched
|
||
Neuroscience
|
||||||||
Diprivan#
|
sedative and anaesthetic
|
conscious sedation
|
Launched
|
2H 2014
|
Launched
|
|||
Oncology
|
||||||||
Caprelsa
|
VEGFR/
EGFR tyrosine kinase inhibitor with RET kinase activity
|
differentiated thyroid cancer
|
2Q 2013
|
2016
|
2016
|
2016
|
||
Faslodex
|
oestrogen receptor antagonist
|
1st line advanced breast cancer
|
4Q 2012
|
2016
|
2016
|
2016
|
2016
|
|
Iressa
|
EGFR tyrosine kinase inhibitor
|
treatment beyond progression
|
1Q 2012
|
2015
|
2015
|
2015
|
||
Respiratory, Inflammation & Autoimmunity
|
||||||||
Symbicort6
|
inhaled steroid/ long-acting β2 agonist
|
Breath Actuated Inhaler asthma /
COPD
|
4Q 2011
|
Compound
|
Mechanism
|
Area Under Investigation
|
Date Commenced Phase
|
Estimated Filing
|
||||||||||
US
|
EU
|
Japan
|
China
|
|||||||||||
Cardiovascular
|
||||||||||||||
Brilinta
/Brilique
|
ADP receptor antagonist
|
arterial thrombosis
|
Launched
|
Launched
|
Filed
|
Launched
|
||||||||
Epanova#
|
omega-3 free fatty acids
|
hypertri-glyceridaemia
|
Filed
|
|||||||||||
Farxiga/
Forxiga1
|
SGLT2 inhibitor
|
diabetes
|
Approved2
|
Launched
|
Filed
|
Filed
|
||||||||
metreleptin
|
leptin analogue
|
lipodystrophy
|
Filed
|
2015
|
N/A
|
|||||||||
Infection
|
||||||||||||||
CAZ AVI (CAZ104)#
|
cephalosporin/beta lactamase inhibitor
|
serious infections
|
1Q 2012
|
N/A
|
4Q 2014
|
2015
|
2016
|
|||||||
CAZ AVI (CAZ104)#
|
cephalosporin/beta lactamase inhibitor
|
hospital-acquired pneumonia/ventilator-associated pneumonia
|
2Q 2013
|
N/A
|
2017
|
2017
|
||||||||
Zinforo (ceftaroline)#
|
extended spectrum cephalosporin with affinity to penicillin- binding proteins
|
pneumonia / skin infections
|
N/A
|
Launched
|
N/A
|
1H 2014
|
||||||||
Neuroscience
|
||||||||||||||
naloxegol (NKTR-118)#
|
oral peripherally-acting mu-opioid receptor antagonist
|
opioid-induced constipation
|
Filed
|
Filed
|
||||||||||
Oncology
|
||||||||||||||
Caprelsa
|
VEGFR / EGFR tyrosine kinase inhibitor with RET kinase activity
|
medullary thyroid cancer
|
Launched
|
Launched
|
3Q 2014
|
Filed
|
||||||||
moxetumomab pasudotox#
|
anti-CD22 recombinant immunotoxin
|
hairy cell leukaemia
|
2Q 2013
|
2018
|
2018
|
|||||||||
olaparib
|
PARP inhibitor
|
gBRCAm
PSR ovarian cancer
|
1Q 2014
|
Filed
|
||||||||||
olaparib SOLO-1
|
PARP inhibitor
|
1st line gBRCAm ovarian cancer
|
3Q 2013
|
2017
|
2017
|
2017
|
2017
|
|||||||
olaparib SOLO-2
|
PARP inhibitor
|
gBRCAm
PSR ovarian cancer
|
3Q 2013
|
2016
|
2016
|
2016
|
2016
|
|||||||
olaparib GOLD
|
PARP inhibitor
|
2nd line gastric cancer
|
3Q 2013
|
2017
|
2018
|
|||||||||
selumetinib (AZD6244) (ARRY-142886)#
|
MEK inhibitor
|
2nd line KRAS+ NSCLC
|
4Q 2013
|
2017
|
2017
|
|||||||||
Respiratory, Inflammation & Autoimmunity
|
||||||||||||||
benralizumab#
|
anti-IL-5R MAb
|
severe asthma
|
4Q 2013
|
2016
|
2016
|
|||||||||
brodalumab#
|
anti-IL-17R MAb
|
psoriasis
|
3Q 2012
|
2015
|
2015
|
|||||||||
lesinurad
|
selective inhibitor of URAT1
|
chronic management of hyperuricaemia in patients with gout
|
4Q 2011
|
2H 2014
|
2H 2014
|
2017
|
||||||||
PT003 GFF
|
LABA/LAMA
|
COPD
|
2Q 2013
|
2015
|
2016
|
|||||||||
Compound
|
Mechanism
|
Area Under Investigation
|
Phase
|
Date Commenced Phase
|
Estimated Filing
|
|||
US
|
EU
|
Japan
|
China
|
|||||
Cardiovascular
|
||||||||
AZD1722#
|
NHE3 inhibitor
|
ESRD-Pi / CKD- with T2DM/ ESRD-Fluid Retention
|
II
|
1Q 2013
|
||||
AZD4901
|
NK3
|
polycystic ovarian syndrome
|
II
|
2Q 2013
|
||||
roxadustat (FG-4592)#
|
hypoxia-inducible factor inhibitor
|
anaemia in CKD/end-stage renal disease
|
II1
|
2018
|
N/A
|
N/A
|
2016
|
|
MEDI6012
|
LCAT
|
ACS
|
I
|
1Q 2012
|
||||
Infection
|
||||||||
AZD5847
|
oxazolidinone anti-bacterial inhibitor
|
tuberculosis
|
II
|
4Q 2012
|
||||
CXL#
|
beta lactamase inhibitor/ cephalosporin
|
MRSA
|
II
|
4Q 2010
|
||||
ATM AVI
|
BL/BLI
|
targeted serious bacterial infections
|
I
|
4Q 2012
|
||||
AZD0914
|
GyrAR
|
serious bacterial infections
|
I
|
4Q 2013
|
||||
MEDI-550
|
pandemic influenza virus vaccine
|
pandemic influenza prophylaxis
|
I
|
2Q 2006
|
||||
MEDI-559 (PRVV)
|
paediatric RSV vaccine
|
RSV prophylaxis
|
I
|
4Q 2008
|
||||
MEDI4893
|
staph alpha toxin YTE MAb
|
hospital-acquired pneumonia / serious S. aureus infection
|
I
|
1Q 2013
|
||||
MEDI92872
|
H7N9 vaccine
|
avian influenza
|
I
|
4Q 2013
|
||||
Neuroscience
|
||||||||
AZD3241
|
myeloper-oxidase (MPO) inhibitor
|
Parkinson's disease
|
II
|
2Q 2012
|
||||
AZD5213
|
histamine-3 receptor antagonist
|
Tourette's syndrome/
neuropathic pain
|
II
|
4Q 2013
|
||||
AZD3293#
|
beta secretase
|
Alzheimer's disease
|
I
|
4Q 2012
|
||||
AZD6423
|
NMDA
|
suicidal ideation
|
I
|
3Q 2013
|
Compound
|
Mechanism
|
Area Under Investigation
|
Phase
|
Date Commenced Phase
|
Estimated Filing
|
|||
US
|
EU
|
Japan
|
China
|
|||||
Oncology
|
||||||||
AZD1775#
|
Wee-1 inhibitor
|
ovarian cancer
|
II
|
4Q 2012
|
||||
AZD2014
|
TOR kinase inhibitor
|
solid tumours
|
II
|
1Q 2013
|
||||
AZD4547
|
FGFR tyrosine kinase inhibitor
|
solid tumours
|
II
|
4Q 2011
|
||||
MEDI-551#
|
anti-CD19 MAb
|
haematological malignancies
|
II
|
1Q 2012
|
||||
MEDI-573#
|
anti-IGF MAb
|
MBC
|
II
|
4Q 2011
|
||||
olaparib
|
PARP inhibitor
|
breast cancer
|
II
|
1Q 2012
|
||||
selumetinib (AZD6244) (ARRY-142886)#
|
MEK inhibitor
|
various cancers
|
II
|
4Q 2008
|
||||
tremelimumab
|
anti-CTLA4 MAb
|
mesothelioma
|
II
|
2Q 2013
|
||||
AZD1208
|
PIM kinase inhibitor
|
haematological malignancies
|
I
|
1Q 2012
|
||||
AZD5363#
|
AKT inhibitor
|
solid tumours
|
I
|
4Q 2010
|
||||
AZD6738
|
ATR
|
CLL/
head & neck
|
I
|
4Q 2013
|
||||
AZD8186
|
PI3 kinase beta inhibitor
|
solid tumours
|
I
|
2Q 2013
|
||||
AZD9150#
|
STAT3 inhibitor
|
haematological malignancies
|
I
|
1Q 2012
|
||||
AZD9291
|
epidermal growth factor inhibitor
|
solid tumours
|
I
|
1Q 2013
|
||||
MEDI-565#
|
anti-CEA BiTE
|
solid tumours
|
I
|
1Q 2011
|
||||
MEDI0639#
|
anti-DLL-4 MAb
|
solid tumours
|
I
|
2Q 2012
|
||||
MEDI0680 (AMP-514)
|
anti-PD-1MAb
|
solid tumours
|
I
|
4Q 2013
|
||||
MEDI3617#
|
anti-ANG-2 MAb
|
solid tumours
|
I
|
4Q 2010
|
||||
MEDI4736#
|
anti-PD-L1 MAb
|
solid tumours
|
I
|
3Q 2012
|
||||
MEDI4736# + tremelimumab
|
anti-PD-L1 MAb + anti-CTLA4 MAb
|
solid tumours
|
I
|
4Q 2013
|
||||
MEDI4736# + dabrafenib + trametinib3
|
anti-PD-L1 MAb + BRAF inhibitor + MEK inhibitor
|
melanoma
|
I
|
1Q 2014
|
||||
MEDI6469#
|
murine anti-OX40 MAb
|
solid tumours
|
I
|
1Q 2006
|
||||
moxetumomab pasudotox#
|
anti-CD22 recombinant immunotoxin
|
pALL
|
I
|
3Q 2008
|
||||
volitinib# (AZD6094)
|
MET inhibitor
|
solid tumours
|
I
|
1Q 2012
|
Compound
|
Mechanism
|
Area Under Investigation
|
Phase
|
Date Commenced Phase
|
Estimated Filing
|
|||
US
|
EU
|
Japan
|
China
|
|||||
Respiratory, Inflammation & Autoimmunity
|
||||||||
AZD2115#
|
MABA
|
COPD
|
II
|
2Q 2012
|
||||
AZD5069
|
CXCR2
|
asthma
|
II
|
4Q 2010
|
||||
benralizumab#
|
anti-IL-5R MAb
|
COPD
|
II
|
4Q 2010
|
||||
brodalumab#
|
anti-IL-17R MAb
|
asthma / psoriatic arthritis
|
II
|
2Q 2013
|
||||
mavrilimumab#
|
anti-GM-CSFR MAb
|
rheumatoid arthritis
|
II
|
1Q 2010
|
||||
MEDI-546#
|
anti-IFN-alphaR MAb
|
SLE
|
II
|
1Q 2012
|
||||
MEDI2070#
|
anti-IL-23 MAb
|
Crohn's disease
|
II
|
1Q 2013
|
||||
MEDI7183#
|
anti-a4b7 MAb
|
Crohn's disease / ulcerative colitis
|
II
|
4Q 2012
|
||||
MEDI8968#
|
anti-IL-1R MAb
|
COPD, HS
|
II
|
4Q 2011
|
||||
RDEA3170
|
selective inhibitor of URAT1
|
chronic management of hyperuricaemia in patients with gout
|
II
|
3Q 2013
|
||||
sifalimumab#
|
anti-IFN-alpha MAb
|
SLE
|
II
|
3Q 2008
|
||||
tralokinumab
|
anti-IL-13 MAb
|
asthma / IPF
|
II
|
1Q 2008
|
||||
AZD1419
|
TLR9
|
asthma
|
I
|
3Q 2013
|
||||
AZD4721
|
CXCR2
|
COPD
|
I
|
3Q 2013
|
||||
AZD7624
|
ip38i
|
COPD
|
I
|
1Q 2013
|
||||
AZD8848#
|
inhaled TLR7
|
asthma
|
I
|
2Q 2012
|
||||
MEDI-551#
|
anti-CD19 MAb
|
multiple sclerosis
|
I
|
3Q 2012
|
||||
MEDI5872#
|
anti-B7RP1 MAb
|
SLE
|
I
|
4Q 2008
|
||||
MEDI9929#
|
anti-TSLP MAb
|
asthma
|
I
|
4Q 2008
|
||||
PT010
|
LAMA/LABA/ICS
|
COPD
|
I
|
4Q 2013
|
NME/Line Extension
|
Compound
|
Reason for Discontinuation
|
Area Under Investigation
|
NME
|
MEDI-557
|
Safety/Efficacy
|
RSV prevention in high risk adults (COPD/CHF/other)
|
NME/Line Extension
|
Compound
|
Reason for Discontinuation
|
Area Under Investigation
|
NME
|
AZD1446
|
Safety/Efficacy
|
Alzheimer's disease
|
NME
|
AZD3480#
|
Safety/Efficacy
|
Alzheimer's disease
|
NME
|
AZD5213
|
Hypothesis risk
|
Alzheimer's disease
|
NME
|
AZD6765
|
Safety/Efficacy
|
major depressive disorder
|
NME
|
MEDI5117
|
Safety/Efficacy
|
OA pain
|
NME/Line Extension
|
Compound
|
Reason for Discontinuation
|
Area Under Investigation
|
NME
|
AZD8330#(ARRY 424704)
|
Safety/Efficacy
|
solid tumours
|
NME
|
fostamatinib#
|
Safety/Efficacy
|
haematological malignancies
|
NME
|
MEDI-575#
|
Safety/Efficacy
|
NSCLC
|
NME/Line Extension
|
Compound
|
Reason for Discontinuation
|
Area Under Investigation
|
NME
|
AZD5423#
|
Safety/Efficacy
|
COPD
|
NME
|
AZD7594#
|
Safety/Efficacy
|
COPD
|
NME
|
fostamatinib#
|
Safety/Efficacy
|
rheumatoid arthritis
|
NME
|
MEDI4212
|
Safety/Efficacy
|
asthma
|
NME
|
MEDI7814
|
Economic
|
COPD
|
LCM
|
tralokinumab
|
Safety/Efficacy
|
UC
|
Compound
|
Mechanism
|
Area Under Investigation
|
Launch Status
|
||||
US
|
EU
|
Japan
|
China
|
||||
Cardiovascular
|
|||||||
Forxiga (dapagliflozin)
|
SGLT2 inhibitor
|
diabetes - add on to DPP-4
|
Approved
|
||||
Forxiga (dapagliflozin)
|
SGLT2 inhibitor
|
diabetes - add on to metformin long-term data
|
Approved
|
||||
Forxiga (dapagliflozin)1
|
SGLT2 inhibitor
|
diabetes - in patients with high CV risk - study 18 and 19 long-term data
|
|||||
Forxiga (dapagliflozin)
|
SGLT2 inhibitor
|
diabetes - triple therapy (dapa+met+ SU)
|
Approved
|
||||
Infection
|
|||||||
Q-LAIV Flu Vaccination
|
live, attenuated, intranasal influenza virus vaccine (quadrivalent)
|
seasonal influenza
|
Approved
|
Approved
|
Date: 06 February 2014
|
By: /s/ Adrian Kemp
|
Name: Adrian Kemp
|
|
Title: Company Secretary
|